Stockscreener 앱 받기
14.97
1.84%
0.27
시간 외 거래:
14.68
-0.29
-1.94%
4 D Molecular Therapeutics Inc 주식(FDMT)의 최신 뉴스
Scott Bizily, 4D Molecular Therapeutics chief legal officer, sells $8,176 By Investing.com - Investing.com Nigeria
4D Molecular Therapeutics (NASDAQ: FDMT) legal chief trades 584 shares at $14 - Stock Titan
4D Molecular Therapeutics (NASDAQ: FDMT) CEO sells 69K shares in preset plan - Stock Titan
4D Molecular Therapeutics (NASDAQ:FDMT) Trading Down 3.7%Here's What Happened - MarketBeat
4D (FDMT) Watch: Advances 13.86% to $16.76; Boundary Watch: Price Remains Between $15.92 Support and $17.60 Resistance in Latest TradingSMA Signal - vinanet.vn
David Kirn plans $1.16M 4D Molecular (NASDAQ: FDMT) stock sale - Stock Titan
HC Wainwright Has Bullish Forecast for FDMT FY2027 Earnings - MarketBeat
4D Molecular Therapeutics CLO Scott Bizily sells $39,567 in stock - Investing.com
146,185 Shares in 4D Molecular Therapeutics, Inc. $FDMT Bought by Perigon Wealth Management LLC - MarketBeat
4D Molecular Therapeutics CLO Scott Bizily sells $39,567 in stock By Investing.com - Investing.com Canada
4D Molecular Therapeutics (NASDAQ:FDMT) Sets New 12-Month HighTime to Buy? - MarketBeat
4D Molecular Therapeutics CLO Scott Bizily Executes Stock Option Exercises and Sales Under 10b5-1 Plan - Kalkine Media
4D Molecular Therapeutics Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs
Scott Bizily Sells 1,635 Shares of 4D Molecular Therapeutics (NASDAQ:FDMT) Stock - MarketBeat
4D Molecular Therapeutics (NASDAQ:FDMT) Insider Scott Bizily Sells 1,635 Shares of Stock - MarketBeat
4D Molecular Therapeutics (NASDAQ: FDMT) legal chief sells 3,270 shares - Stock Titan
Scott Bizily plans new 4D Molecular (NASDAQ: FDMT) sale after 10b5-1 stock trades - Stock Titan
4D Molecular Therapeutics (NASDAQ:FDMT) Shares Up 10%Time to Buy? - MarketBeat
Persistent Asset Partners Ltd Makes New $1.94 Million Investment in 4D Molecular Therapeutics, Inc. $FDMT - MarketBeat
Analysts Offer Insights on Healthcare Companies: 4D Molecular Therapeutics (FDMT), Alto Neuroscience, Inc. (ANRO) and Irhythm Technologies (IRTC) - The Globe and Mail
4DMT Announces New Employment Inducement Grants - The Manila Times
H.C. Wainwright reiterates Buy on 4D Molecular stock, $36 target By Investing.com - Investing.com Nigeria
4D Molecular Therapeutics, Inc. (FDMT) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance
4D Molecular Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Is 4D Molecular Therapeutics Inc (FDMT) Undervalued After Q2 Ear - GuruFocus
4D Molecular Therapeutics (NASDAQ:FDMT) Announces Quarterly Earnings Results - MarketBeat
FDMT (NASDAQ: FDMT) stockholder schedules 1,635-share sale after option exercise - Stock Titan
4D Molecular Therapeutics (FDMT) posts $141.7M first-half 2026 net loss - Stock Titan
4DMT Reports Second Quarter 2026 Financial Results, Operational Highlights and Expected Upcoming Milestones - The Manila Times
Dimensional Fund Advisors LP Purchases 227,982 Shares of 4D Molecular Therapeutics, Inc. $FDMT - MarketBeat
4D Molecular Therapeutics (FDMT) Short Interest & Short Float | Updated Aug 2026 - MarketBeat
4D Molecular Therapeutics Inc (FDMT) Stock News Today - TradingKey
4D Molecular Therapeutics Inc (FDMT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
4D Molecular Therapeutics Inc expected to post a loss of $1.02 a shareEarnings Preview - TradingView
4D Molecular Therapeutics Inc (FDMT) Stock Price, Trades & News - GuruFocus
4D Molecular Therapeutics, Inc. (FDMT) insider sells 26,842 shares under plan - Stock Titan
Ken Fisher's 4D Molecular Therapeutics Inc(FDMT) Holding History - GuruFocus
4D Molecular Therapeutics (FDMT) Insider David Kirn Sells 12,415 Shares - GuruFocus
FDMT (FDMT) insider plans 26,842-share Class A sale after sizable prior trades - Stock Titan
David Kirn Sells 12,415 Shares of 4D Molecular Therapeutics (NASDAQ:FDMT) Stock - MarketBeat
4D Molecular Therapeutics (FDMT) CEO sells 12,415 shares via 10b5-1 plan - Stock Titan
Enterprise value to revenue forward of 4D Molecular Therapeutics, Inc. – NASDAQ:FDMT - TradingView
Form 144 4D Molecular Therapeutics For: 4 August By Investing.com - Investing.com Nigeria
FDMT (FDMT) investor David Kirn plans Rule 144 sale of 12,415 shares - Stock Titan
Janus Henderson Group PLC Acquires 611,276 Shares of 4D Molecular Therapeutics, Inc. $FDMT - MarketBeat
4D Molecular Therapeutics (NASDAQ:FDMT) Rating Increased to Strong-Buy at Chardan Capital - MarketBeat
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
4D Molecular Therapeutics, Inc. Revenue Breakdown – NASDAQ:FDMT - tradingview.com
Exome Asset Management LLC Purchases New Position in 4D Molecular Therapeutics, Inc. $FDMT - MarketBeat
4D Molecular Therapeutics Inc (FDMT) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
4D Molecular Therapeutics Inc (FDMT) Income Statement - tradingkey.com
4D Molecular Therapeutics Inc (FDMT) Valuation: PE, PB & Fair Value Analysis - TradingKey
FDMT|4D Molecular Therapeutics Inc|Price:10.380|Chg%:+0.310 - TradingKey
4D Molecular Therapeutics Inc (FDMT) Balance Sheet - TradingKey
4D Molecular Therapeutics Inc (FDMT) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
4D Molecular Therapeutics Inc. (FDMT) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
FDMT|4D Molecular Therapeutics Inc|Price:16.530|Chg%:+1.810 - TradingKey
4D Molecular Therapeutics Inc (FDMT) Institutional Confidence - TradingKey
4D Molecular Therapeutics Inc (FDMT) Cash Flow - TradingKey
4D Molecular Therapeutics (FDMT) Slips Over 2% – Key Levels Under ScrutinyTPO Profile - vinanet.vn
4D Molecular Therapeutics Inc - TradingKey
4D Molecular Therapeutics Inc (FDMT) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
FDMT|4D Molecular Therapeutics Inc|Price:10.070|Chg%:-0.310 - TradingKey
4D Molecular releases phase 2 data for wet AMD asset 4D-150 - MSN
0.86%
0.31%
자본화:
|
볼륨(24시간):